Physician profile
Dharini Sun
NPI 1558355743
$2,350.67
in general payments reported to CMS, 2019-2025
35 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $606 · 2021: $179 · 2022: $36.09 · 2023: $94.24 · 2024: $299 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $303.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $267.68 | 2019-2025 | Wegovy |
| Amgen INC. | $189.34 | 2019-2025 | Evenity, Enbrel, Otezla |
| Amarin Pharma, INC. | $178.55 | 2019-2020 | |
| Glaxosmithkline, LLC. | $120.25 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $114.10 | 2019-2025 | |
| Genzyme Corporation | $110.00 | 2019 | |
| Abbvie INC. | $96.95 | 2020-2024 | |
| Scilex Pharmaceuticals INC. | $76.46 | 2019 | |
| Endo Pharmaceuticals INC. | $67.38 | 2019-2020 | |
| Allergan, INC. | $66.50 | 2019-2020 | |
| Eisai INC. | $55.61 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.34 | 2019-2025 | Jardiance |
| Janssen Biotech, INC. | $49.67 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $48.34 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $42.14 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.25 | 2024 | Orencia |
| Astellas Pharma US INC | $39.44 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $38.90 | 2019-2024 | Capvaxive |
| Acorda Therapeutics, INC | $38.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.64 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.09 | 2022 | |
| Currax Pharmaceuticals LLC | $34.42 | 2020 | |
| Janssen Pharmaceuticals, INC | $32.01 | 2019 | |
| Alexion Pharmaceuticals, INC. | $26.92 | 2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $26.81 | 2025 | Unithroid |
| Ucb, INC. | $26.14 | 2025 | Bimzelx |
| Neurocrine Biosciences, INC. | $24.08 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.76 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $17.52 | 2020 | |
| Avanir Pharmaceuticals, INC. | $16.51 | 2020 | |
| Genentech USA, INC. | $15.83 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.32 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.17 | 2019 | |
| Seqirus USA INC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharini Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.